MAFLD, patient-centred care, and APASL

Area of Science:

• Hepatology
• Metabolic Disorders
• Public Health

Background:

• Metabolic dysfunction associated fatty liver disease (MAFLD) is the primary driver of chronic liver disease in the Asia-Pacific region, affecting over half the global population.
• The prevalence of MAFLD presents significant challenges for large-scale disease management and research within the region.

Purpose of the Study:

• To highlight the Asian Pacific Association for the Study of the Liver's (APASL) initiative in redefining fatty liver disease.
• To advocate for the adoption of the term "Metabolic dysfunction associated fatty liver disease" (MAFLD) and its positive diagnostic criteria.
• To promote advancements in Hepatology and multidisciplinary care for MAFLD patients.

Main Methods:

• Endorsement and leadership by APASL in redefining the terminology and diagnostic criteria for fatty liver disease.
• Collaboration with international sister societies to promote the widespread adoption of the MAFLD definition.
• Focus on developing innovative clinical trial designs for metabolic dysfunction-related liver diseases.

Main Results:

• APASL has pioneered the adoption of the term "Metabolic dysfunction associated fatty liver disease" (MAFLD) with positive diagnostic criteria.
• The initiative aims to advance Hepatology science and integrate MAFLD into multidisciplinary care.
• Anticipated outcomes include improved clinical trial designs and holistic, person-centered care for MAFLD patients.

Conclusions:

• The adoption of the MAFLD definition by APASL is a critical step towards advancing the understanding and management of metabolic dysfunction-related liver disease in the Asia-Pacific.
• Continued collaboration and the implementation of innovative care models are essential for improving patient outcomes.
• This shift will facilitate more effective research and person-centered care for this prevalent condition.